Cargando…

Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy

BACKGROUND: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case...

Descripción completa

Detalles Bibliográficos
Autores principales: Dózsai, Dávid, Ecseri, Tamás, Csonka, István, Gárgyán, István, Doró, Péter, Csonka, Ákos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493328/
https://www.ncbi.nlm.nih.gov/pubmed/32933566
http://dx.doi.org/10.1186/s13018-020-01941-x
_version_ 1783582545325064192
author Dózsai, Dávid
Ecseri, Tamás
Csonka, István
Gárgyán, István
Doró, Péter
Csonka, Ákos
author_facet Dózsai, Dávid
Ecseri, Tamás
Csonka, István
Gárgyán, István
Doró, Péter
Csonka, Ákos
author_sort Dózsai, Dávid
collection PubMed
description BACKGROUND: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case reports found that PFFs can occur with characteristics similar to those of AFFs. The purpose of our study was to evaluate the proportion of atypical fractures among Vancouver type B1 fractures, and to determine the association between the long-term use of bisphosphonates and the occurrence of atypical periprosthetic femoral fractures (APFFs). METHODS: In this retrospective study, we reviewed 41 patients with Vancouver type B1 periprosthetic fractures between January 1, 2011 and December 31, 2018. We classified them into two groups, namely atypical and typical PFFs, based on the fracture morphology. We noted the proportion of atypical periprosthetic fractures among B1 fractures and identified risk factors. RESULTS: Among the 41 PFFs, 5 (13%) fractures were classified as atypical PFF based on the radiological characteristics. The longer duration of bisphosphonate use was probably the only independent risk factor that significantly increases the occurrence of APFF (p = 0.03, 0.08 (CI 0.008 – 0.16)). There were no significant differences in age, gender, body mass index, comorbidities, corticosteroid use, positioning of the femoral stem, the method of fixation (cemented or cementless) and time lapse from before the primary prosthesis implantation to the PFF in the development of atypical fracture type. CONCLUSIONS: There seems to be a correlation between the long-term intake of bisphosphonates and the atypical periprosthetic fracture. Atypical femoral fracture can also occur in the periprosthetic form. TRIAL REGISTRATION: Study number: 22/2019-SZTE, http://www.klinikaikutatas.hu/hu/kutatasetika/jovahagyott-vizsgalatok-koezerdeku-adatai/category/25-jovahagyott-vizsgalatok-kozerdeku-adatai-rkeb-2019.html?download=985:22-2019.
format Online
Article
Text
id pubmed-7493328
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74933282020-09-16 Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy Dózsai, Dávid Ecseri, Tamás Csonka, István Gárgyán, István Doró, Péter Csonka, Ákos J Orthop Surg Res Research Article BACKGROUND: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case reports found that PFFs can occur with characteristics similar to those of AFFs. The purpose of our study was to evaluate the proportion of atypical fractures among Vancouver type B1 fractures, and to determine the association between the long-term use of bisphosphonates and the occurrence of atypical periprosthetic femoral fractures (APFFs). METHODS: In this retrospective study, we reviewed 41 patients with Vancouver type B1 periprosthetic fractures between January 1, 2011 and December 31, 2018. We classified them into two groups, namely atypical and typical PFFs, based on the fracture morphology. We noted the proportion of atypical periprosthetic fractures among B1 fractures and identified risk factors. RESULTS: Among the 41 PFFs, 5 (13%) fractures were classified as atypical PFF based on the radiological characteristics. The longer duration of bisphosphonate use was probably the only independent risk factor that significantly increases the occurrence of APFF (p = 0.03, 0.08 (CI 0.008 – 0.16)). There were no significant differences in age, gender, body mass index, comorbidities, corticosteroid use, positioning of the femoral stem, the method of fixation (cemented or cementless) and time lapse from before the primary prosthesis implantation to the PFF in the development of atypical fracture type. CONCLUSIONS: There seems to be a correlation between the long-term intake of bisphosphonates and the atypical periprosthetic fracture. Atypical femoral fracture can also occur in the periprosthetic form. TRIAL REGISTRATION: Study number: 22/2019-SZTE, http://www.klinikaikutatas.hu/hu/kutatasetika/jovahagyott-vizsgalatok-koezerdeku-adatai/category/25-jovahagyott-vizsgalatok-kozerdeku-adatai-rkeb-2019.html?download=985:22-2019. BioMed Central 2020-09-15 /pmc/articles/PMC7493328/ /pubmed/32933566 http://dx.doi.org/10.1186/s13018-020-01941-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Dózsai, Dávid
Ecseri, Tamás
Csonka, István
Gárgyán, István
Doró, Péter
Csonka, Ákos
Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title_full Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title_fullStr Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title_full_unstemmed Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title_short Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
title_sort atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493328/
https://www.ncbi.nlm.nih.gov/pubmed/32933566
http://dx.doi.org/10.1186/s13018-020-01941-x
work_keys_str_mv AT dozsaidavid atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy
AT ecseritamas atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy
AT csonkaistvan atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy
AT gargyanistvan atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy
AT doropeter atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy
AT csonkaakos atypicalperiprostheticfemoralfractureassociatedwithlongtermbisphosphonatetherapy